Opinion
Video
The Role of Novel Targeted Therapies
Author(s):
A panelist discusses how novel targeted therapies such as antibody-drug conjugates are rapidly evolving in gynecologic oncology, with multiple agents targeting different biomarkers in development, though optimal sequencing strategies remain to be determined.
Video content is prompted by the following:
Novel Targeted Therapies in the Treatment Landscape
Key Themes:
- Emergence of antibody-drug conjugates (ADCs) targeting various receptors
- Movement of ADCs into earlier treatment settings
- Biomarker-directed therapy approach
Notable Insights:
- Multiple ADCs are in development with different targeting mechanisms and payloads:
- Mirvetuximab soravtansine (folate receptor alpha, microtubule toxin)
- Renatabart cecitakin (folate receptor alpha, exatecan payload)
- Trastuzumab deruxtecan (HER2, deruxtecan payload)
- Relutagimod deruxtecan (cadherin-6, deruxtecan payload)
- TORL-1-23 (claudin-6, MMAE payload)
- ADCs are moving from platinum-resistant settings into maintenance therapy and frontline treatment:
- GLORIOSA trial: mirvetuximab plus bevacizumab maintenance after second-line platinum
- Trastuzumab deruxtecan trials in HRD-negative frontline maintenance
- Dr Moore emphasized that these are “very effective medications” but acknowledged: “We’re excited, but there’s a lot we have to learn...there’s just going to be quite a bit of work to do in the next years to really sort this out, to optimize for patients.”
Related Content
